 | Up a level |
Rabaglio, Manuela; Sun, Zhuoxin; Maibach, Rudolf; Giobbie-Hurder, Anita; Ejlertsen, Bent; Harvey, Vernon J; Neven, Patrick; Láng, István; Bonnefoi, Hervé; Wardley, Andrew; Ruepp, Barbara; Castiglione, Monica; Coates, Alan S; Gelber, Richard D; Goldhirsch, Aron; Colleoni, Marco; Thürlimann, Beat; Regan, Meredith M (2020). Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial. Breast cancer research and treatment, 185(3), pp. 697-707. Springer 10.1007/s10549-020-05981-z
Loi, Sherene; Giobbie-Hurder, Anita; Gombos, Andrea; Bachelot, Thomas; Hui, Rina; Curigliano, Giuseppe; Campone, Mario; Biganzoli, Laura; Bonnefoi, Hervé; Jerusalem, Guy; Bartsch, Rupert; Rabaglio, Manuela-Poretti; Kammler, Roswitha; Maibach, Rudolf; Smyth, Mark J; Di Leo, Angelo; Colleoni, Marco; Viale, Giuseppe; Regan, Meredith M and André, Fabrice (2019). Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. The lancet oncology, 20(3), pp. 371-382. Elsevier 10.1016/S1470-2045(18)30812-X
Ewertz, Marianne; Gray, Kathryn P; Regan, Meredith M; Ejlertsen, Bent; Price, Karen N; Thürlimann, Beat; Bonnefoi, Hervé; Forbes, John F; Paridaens, Robert J; Rabaglio, Manuela; Gelber, Richard D; Colleoni, Marco; Láng, István; Smith, Ian E; Coates, Alan S; Goldhirsch, Aron; Mouridsen, Henning T (2012). Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. Journal of clinical oncology, 30(32), pp. 3967-75. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2011.40.8666
Sabbioni, Marzio E E; Bernhard, Jürg; Siegrist, Hans-Peter; Schmitz, Shu-Fang Hsu; Gertsch, Monica Castiglione; Thürlimann, Beat; Bonnefoi, Hervé; Perey, Lucien; Herrmann, Richard; Goldhirsch, Aron; Hürny, Christoph; Swiss Group for Clinical Cancer Research, (SAKK) (2004). Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy? Breast cancer research and treatment, 87(1), pp. 75-86. Dordrecht: Springer 10.1023/B:BREA.0000041584.53863.a7
